Loading...
•
Dec 31, 2024
Aytu BioScience Q2 2025 Earnings Report
Aytu BioPharma reported its fiscal 2025 second quarter operational and financial results, showing a net income of $0.8 million and adjusted EBITDA of $1.3 million.
Key Takeaways
Aytu BioPharma reported a net income of $0.8 million and adjusted EBITDA of $1.3 million for the second quarter of fiscal 2025. The company saw an 86% sequential increase in Pediatric Portfolio net revenue and a 16% sequential increase in ADHD Portfolio net revenue, marking the first quarterly sequential prescription increase for both portfolios since Q2 fiscal 2023.
Net income for Q2 fiscal 2025 was $0.8 million, or $0.13 net income per share basic.
Adjusted EBITDA for Q2 fiscal 2025 was $1.3 million.
Pediatric Portfolio net revenue increased 86% sequentially to $2.4 million.
ADHD Portfolio net revenue increased 16% sequentially to $13.8 million.
Revenue by Segment
Forward Guidance
Aytu BioPharma expects continued revenue and adjusted EBITDA growth, driven by strategic realignments, operational efficiencies, and potential in-licensed or acquired products. The company aims to generate positive cash flows and increase stockholder value.
Positive Outlook
- Expects to realize at least $2.0 million in annual cost savings from corporate optimization initiatives.
- Aims to generate positive cash flows and increase stockholder value.
- Focused on commercializing novel prescription therapeutics and leveraging its streamlined organization.
- Seeking opportunities to leverage commercial infrastructure and Aytu RxConnect platform.
- Pursuing additional in-licensed or acquired products to drive future growth.
Challenges Ahead
- The company's ADHD inventory has a higher cost due to allocation of overhead costs from the Grand Prairie, Texas manufacturing facility to reduced production, which is expected to normalize in coming quarters.
- Gross profit percentage decreased to 66% from 78% in the prior year, primarily due to increased cost of sales in ADHD inventory.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...